Compound A influences gene regulation of the dexamethasone-activated glucocorticoid receptor by alternative cofactor recruitment by Desmet, Sofie et al.
1Scientific RepoRts | 7: 8063  | DOI:10.1038/s41598-017-07941-y
www.nature.com/scientificreports
Compound A influences gene 
regulation of the Dexamethasone-
activated glucocorticoid receptor 
by alternative cofactor recruitment
S. J. Desmet1,2,3, N. Bougarne1,2,3, L. Van Moortel1,2,3, L. De Cauwer1,2,3, J. Thommis1,2,3,  
M. Vuylsteke4, D. Ratman1,2,3,6, R. Houtman5, J. Tavernier2,3 & K. De Bosscher1,2,3
The glucocorticoid receptor (GR) is a transcription factor of which the underlying gene regulatory 
mechanisms are complex and incompletely understood. The non-steroidal anti-inflammatory 
Compound A (CpdA), a selective GR modulating compound in various cell models, has been shown 
to favour GR-mediated gene repression but not GR-mediated gene activation. Shifting balances 
towards only a particular subset of GR gene regulatory events may be of benefit in the treatment 
of inflammatory diseases. We present evidence to support that the combination of CpdA with 
Dexamethasone (DEX), a classic steroidal GR ligand, can shape GR function towards a unique 
gene regulatory profile in a cell type-dependent manner. The molecular basis hereof is a changed 
GR phosphorylation status concomitant with a change in the GR cofactor recruitment profile. We 
subsequently identified and confirmed the orphan nuclear receptor SHP as a coregulator that is 
specifically enriched at GR when CpdA and DEX are combined. Combining CpdA with DEX not only leads 
to stronger suppression of pro-inflammatory gene expression, but also enhanced anti-inflammatory GR 
target gene expression in epithelial cells, making ligand combination strategies in future a potentially 
attractive alternative manner of skewing and fine-tuning GR effects towards an improved therapeutic 
benefit.
Glucocorticoids (GCs) are steroid hormones derived from cholesterol and secreted by the adrenal glands. As they 
play a pivotal role in various physiological processes, including glucose metabolism and stress responses, their 
synthesis is under strict control by the hypothalamic-pituitary-adrenal (HPA) axis and furthermore subjected 
to circadian and ultradian rhythms. GCs exert their pleiotropic actions through the glucocorticoid receptor α 
(GR), a ligand-dependent transcription factor (TF) belonging to the nuclear receptor superfamily1–3. Due to 
their hydrophobic nature, GCs diffuse freely through the cellular membrane and bind to the receptor, which in 
the unliganded state resides in cytoplasm via binding to its chaperone complex. Binding of the receptor to its 
GC ligand induces a conformational change, followed by nuclear translocation. Once in the nucleus, the GR can 
activate its target genes by homodimer binding onto cognate DNA sequences, termed glucocorticoid response 
elements (GRE), a mechanism referred to as transactivation. Additionally, the GR can interfere with the activities 
of various pro-inflammatory TFs, including nuclear factor κB (NF-kB), without the necessity of DNA binding4. 
This mechanism, called transrepression, is associated with the well-known anti-inflammatory actions of GR. 
Several coregulators, which can be both coactivators and/or corepressors, are recruited by the receptor to enable 
GR-mediated transcriptional activities. These proteins have diverse functions, including bridging GR with the 
transcription initiation complex5. Peroxisome proliferator-activated receptor coactivator 1α (PGC-1α) for exam-
ple, which binds to several members of the NR superfamily, typically enhances the NR-mediated transcription6. 
In contrast, small heterodimer partner (SHP) acts as a transcriptional (co-)repressor of gene expression in a wide 
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array of biological pathways. SHP belongs to the NR0B subfamily, which lack a DNA-binding domain (DBD). 
This orphan nuclear receptor functions by virtue of its ability to bind directly to multiple NRs and TFs7, 8.
GCs, also referred to as corticosteroids, are widely used in the clinic for their anti-inflammatory and immune 
modulatory actions. Unfortunately, the therapeutic benefits are overshadowed by the occurrence of deleterious 
side effects and GC resistance. For these reasons, a whole range of so-called selective GR agonists and mod-
ulators (SEGRAMs) have been characterized and/or developed, aimed at displaying a more dissociative pro-
file, i.e. favouring GR-mediated transrepression over transactivation. Among those, Compound A (CpdA), a 
plant-derived compound supporting GR-mediated anti-inflammatory activities, does not stimulate GRE-driven 
gene expression9–16. However, only few dissociative compounds have reached the clinic17, 18, and there is still a 
need for anti-inflammatory therapies with a better therapeutic index.
In the current work, we present data demonstrating an advantageous profile of GR ligand/modulator com-
binations, more precisely the combination of the full agonist Dexamethasone (DEX) with the SEGRAM CpdA.
Results
Combining DEX with CpdA enhances the repression of an NF-κB-dependent reporter and 
reduces the transactivation activity on a GRE-dependent reporter. Both the classic agonist DEX 
and the SEGRAM CpdA inhibit inflammation through interference with the activity of NF-κB9, 19–21. In contrast 
to DEX, however, CpdA does not stimulate GRE-dependent gene expression. This ligand-dependent functional 
outcome, combined with the finding that CpdA elicits a different GR conformation compared to DEX9, led us to 
postulate that CpdA may modulate a DEX-triggered GR. To test this hypothesis, we investigated the functional 
outcome upon combining the classic GR ligand, DEX, with the GR modulator, CpdA. In our previous work9, 
where CpdA was added to cells 1 h before DEX, using a GRE-dependent reporter as a read-out, both ligands 
seemed to functionally compete for the receptor. Oddly, this was not the case when added simultaneously. Hence, 
we first verified the effect of a pre-treatment with CpdA on the activity of DEX-induced p(GRE)2–50-Luc+, a 
recombinant GRE-driven reporter gene stably integrated in L929sA cells. DEX, in contrast to CpdA, strongly acti-
vated the promoter in a dose-dependent manner (Fig. 1a). In line with our earlier findings9, CpdA significantly 
lowers the DEX-induced promoter activity. This result was confirmed in A549 cells, upon using the highest DEX 
concentration of 1 µM (Supplementary Figure S1a), with no effects on cell viability (Supplementary Figure S1b).
To determine the combined effect of CpdA and DEX on the transrepression potential of GR, we used 
p(IL6-κB)3–50hu.IL6P-luc+, an NF-κB-dependent promoter construct stably integrated in L929sA cells. As 
expected, both DEX and CpdA efficiently downregulated TNFα-activated reporter activity when added sepa-
rately (Fig. 1b). Addition of CpdA before DEX however, clearly enhanced this suppression.
Figure 1. Combining DEX with CpdA enhances the repression of an NF-κB-dependent reporter and reduces 
the transactivation activity on a GRE-dependent reporter. (a) L929sA cells with a stably integrated p(GRE)2-
50-luc+, a GRE-dependent promoter construct, were pre-incubated with CpdA (10 µM) for 1 h, after which 
three different concentrations of DEX (10−6 M, 10−7 M and 10−8 M) were added for 5 h. Promoter activities are 
expressed as relative induction factor versus Solvent/No CpdA. Four independent replicates were performed. 
Means + SE, obtained as predictions from the HGLMM fitted to the data, are shown on the original scale. (b) 
L929sA cells with a stably integrated p(IL6-κB)3-50hu.IL6P-luc+, a NF-κB-dependent promoter construct, 
were sequentially stimulated with CpdA (10 µM for 6 h), DEX (1 µM for 5 h) and TNFα (2000 units/ml for 4 h) 
with 1 h between stimulations. Promoter activities are expressed as relative induction factor versus Untreated. 
Five independent replicates were performed. Means + SE, obtained as predictions from the HGLMM fitted to 
the data, are shown on the original scale. The significance of ligand combination effects on reporter activity, 
estimated as differences (on the transformed scale) to the reference level CpdA/DEX, were assessed using a 
t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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Figure 2. Combining CpdA with a non-saturating DEX concentration suppresses particular inflammatory 
genes, both at the mRNA and protein level. (a) Scheme of the experimental set-ups. (b) A549 cells were 
sequentially stimulated with TNFα (2000 units/ml for 4 h), CpdA (10 µM) and DEX (10 nM) with 1 h between 
stimulations. Total RNA was extracted and subjected to RT-qPCR. Expression values were normalized to the 
reference genes Cyclo and HPRT using qBase+. Five independent replicates were performed. Means + SE, 
obtained as predictions from the HGLMM fitted to the data, are shown on the original scale for CCL2, CCL5, 
TNFα and ICAM. (c) A549 cells were sequentially stimulated with CpdA (10 µM, for 6 h), DEX (10 nM) 
and TNFα (2000 units/ml) with 1 h between stimulations. Total RNA was extracted and subjected to RT-
qPCR. Expression values were normalized to the reference genes Cyclo and HPRT using qBase+. At least four 
independent replicates were performed. Means + SE, obtained as predictions from the HGLMM fitted to the 
data, are shown on the original scale for CCL2, CCL5, TNFα and ICAM. (d) A549 cells were sequentially 
stimulated with TNFα (2000 units/ml for 8 or 24 h), CpdA (10 µM) and DEX (10 nM) with 1 h between 
stimulations. Culture supernatant was harvested and measured with sandwich ELISA for CCL2 protein. 
Three independent replicates, normalized using a standard curve, were performed. Means + SE, obtained as 
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Combining CpdA with a non-saturating DEX concentration suppresses particular inflammatory 
genes, both at the mRNA and protein level. In a classic set-up to score anti-inflammatory effects in 
vitro, compounds are often administered before the inflammatory stimulus. However, there are two major draw-
backs to this methodology. First, this set-up does not answer whether the compound can modulate an ongoing 
inflammatory response, which is the most likely situation in clinic. Second, it becomes increasingly clear that the 
sequence in which GC treatment and immune challenge follow each other impacts the final inflammatory out-
come. GCs administered prior to the immune challenge could even potentiate the pro-inflammatory response, 
whereas addition of the GCs after the challenge mostly suppresses ongoing inflammation (reviewed recently in 
ref. 22). For these reasons, we compared a classic “prophylactic” set-up to a “therapeutic” set-up. The duration 
(4 h) of the inflammatory challenge was kept identical (depicted in Fig. 2a) to further investigate the combined 
action of (pre-treated) CpdA and DEX on endogenous gene expression. We further decided to lower the DEX 
concentration to 10 nM to avoid reaching a maximal response already upon using DEX alone. From a therapeutic 
perspective, a combination therapy may offer the additional advantage that when the GC dose can be lowered 
without sacrificing therapeutic effectiveness, the side effects associated with prolonged high-dose GC use can be 
diminished.
Because airway epithelial cells are at the front line of human defence mechanisms and capable of initiating an 
innate inflammatory response, we examined the combined effect of DEX (10 nM) and CpdA on TNFα-induced 
expression in the human respiratory epithelial cell line A549. In line with the data presented in Fig. 1b, combining 
CpdA with DEX resulted in an enhanced suppression of the pro-inflammatory genes CCL2, CCL5, TNFα and 
ICAM, compared to DEX or CpdA alone (Fig. 2b and c). Both experimental set-ups displayed a similar overall 
expression pattern and consistent enhanced suppression when combining (pre-treated) CpdA with DEX. Mild 
variations between the two set-ups possibly reflect gene-specific sensitivities and/or the fact that the ligands have 
been on the cells for a longer period of time in the prophylactic set-up, potentially allowing for additional second-
ary effects. We further measured CCL2 protein using the more physiologically relevant therapeutic set-up, hereby 
confirming that stronger gene suppression at the mRNA level translates to diminished protein levels. Indeed, after 
both 8 h and 24 h induction (Fig. 2d), the combined action of (pre-treated) CpdA and DEX resulted in a stronger 
suppression of CCL2 production, compared to DEX or CpdA stimulation alone.
Finally, we checked whether pre-treatment of CpdA is a prerequisite for these effects, by comparing the results 
to a set-up in which CpdA and DEX are added simultaneously (Supplementary Figure S2). In both experimen-
tal set-ups (depicted in Supplementary Figure S2a), a simultaneous combination of CpdA and DEX could also 
enhance the suppression of the pro-inflammatory genes CCL2, CCL5, TNFα and ICAM, compared to DEX or 
CpdA alone (Supplementary Figure S2b,c).
In conclusion, the results with endogenous GR target genes correspond with the above observed enhanced 
effect on the GR-mediated transrepression of NF-κB-dependent promoter activity, when combining the non-
steroidal GR modulator, CpdA, with the steroidal ligand, DEX.
The effect of CpdA on DEX-induced gene expression is gene-specific. Because we observed a mark-
edly diminished transactivation potential of DEX-activated GR upon adding CpdA (Fig. 1a and Supplementary 
Figure S1a), we wanted to explore this further at the level of endogenous GR target genes. First, we used the 
non-saturating DEX concentration (10 nM) in both the absence and presence of serum, while applying two 
time periods (3 h and 6 h of CpdA stimulation) (Fig. 3a–d). As expected, all GRE-dependent genes tested were 
strongly induced by DEX. In line with the reporter assays (Fig. 1a), CpdA pre-treatment strongly suppressed the 
DEX-mediated induction of FK506-binding protein 5 (FKBP5), a well-known GRE-dependent gene. Intriguingly, 
the combined effect appears gene-specific, as the ligand combination either had no effect or even enhanced the 
expression of other GRE-dependent genes, exemplified by the anti-inflammatory dual specificity phosphatase 1 
(DUSP1) and glucocorticoid-induced leucine zipper (GILZ) gene. These trends remain similar across the differ-
ent starvation methods and time periods. Surprisingly, at the shorter time period in the absence of serum, CpdA 
alone could induce the expression of DUSP1 (Fig. 3a). At the same time period, the presence of serum enhances 
the expression level of GILZ when combining CpdA with DEX, albeit not dramatically (Fig. 3, compare panel a 
and c for GILZ).
Second, we also tested the higher DEX concentration (1 µM) with 6 h of CpdA stimulation, corresponding to 
the conditions used in the reporter assays of Fig. 1 and Supplementary Figure S1. Supplementary Figure S3a–b 
shows that at this higher DEX concentration, similar expression patterns and trends are visible upon addition of 
CpdA. To further investigate the effects on endogenous genes we continued with the non-saturating DEX concen-
tration (10 nM), due to fact that this lower dose corresponds with lower side effects, which is the more desirable 
situation in the clinic.
Finally, similarly as for the transrepression assays (Supplementary Figure S2), we tested the effect of a simul-
taneous addition of CpdA and DEX on the endogenous GR target genes in the absence of serum (Supplementary 
Figure S3c). These results indicate that even when added simultaneously, CpdA can suppress the DEX-mediated 
induction of FKBP5. Still, the pre-treatment set-up appears to exhibit a more outspoken effect.
In conclusion, these findings indicate that CpdA consistently influences DEX-activated GR-mediated gene 
expression, under varying cellular conditions and in a gene-specific manner.
predictions from the HGLMM fitted to the data, are shown on the original scale. The significance of (gene-
specific) ligand combination effects on inflammatory gene or protein expression, estimated as differences (on 
the transformed scale) to the (gene-specific) reference level CpdA/DEX, were assessed using a t-test (*p < 0.05; 
**p < 0.01; ***p < 0.001).
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Figure 3. The effect of CpdA stimulation on DEX-induced gene expression is gene-specific. (a) Serum-starved 
A549 cells were pre-incubated with CpdA (10 µM) for 1 h, after which DEX (10 nM) was added for 2 h. Total 
RNA was extracted and subjected to RT-qPCR. Expression values were normalized to the reference genes 
B2M and HPRT using qBase+. At least four independent replicates were performed. Means +SE, obtained as 
predictions from the HGLMM fitted to the data, are shown on the original scale for FKBP5, DUSP1 and GILZ. 
(b) Serum-starved A549 cells were pre-incubated with CpdA (10 µM) for 1 h, after which DEX (10 nM) was 
added for 5 h. Total RNA was extracted and subjected to RT-qPCR. Expression values were normalized to the 
reference genes B2M and HPRT using qBase+. At least three independent replicates were performed. Means 
+SE, obtained as predictions from the HGLMM fitted to the data, are shown on the original scale for FKBP5, 
DUSP1 and GILZ. (c) A549 cells were pre-incubated with CpdA (10 µM) for 1 h, after which DEX (10 nM) was 
added for 2 h. Total RNA was extracted and subjected to RT-qPCR. Expression values were normalized to the 
reference genes Cyclo and HPRT using qBase+. Three independent replicates were performed. Means + SE, 
obtained as predictions from the HGLMM fitted to the data, are shown on the original scale for FKBP5, DUSP1 
and GILZ. (d) A549 cells were pre-incubated with CpdA (10 µM) for 1 h, after which DEX (10 nM) was added 
for 5 h. Total RNA was extracted and subjected to RT-qPCR. Expression values were normalized to the reference 
genes B2M and HPRT using qBase+. Three independent replicates were performed. Means + SE, obtained as 
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The effect of CpdA on DEX-induced gene expression is more pronounced in mICcl2 cells, in the 
presence of serum. Next, we wondered whether CpdA influenced DEX-induced GR target gene expression 
in the same manner, using another epithelial cell line. For this purpose, we studied mICcl2 cells, which are posi-
tioned as a first line of defence in the small intestinal tissue. Both epithelial cell lines express GR protein levels to a 
similar extent (see Supplementary Figure S4). In analogy with Fig. 3, we tested both starvation methods and time 
periods in the mICcl2 cells, and measured mRNA levels of FKBP5, DUSP1 and GILZ. As expected, DEX induced 
the expression of all three genes. This is in contrast to CpdA, at least for FKBP5 and GILZ (Fig. 4). Surprisingly, 
in the presence of serum, CpdA alone significantly induced DUSP1 to a similar extent as the non-saturating DEX 
concentration (Fig. 4c). This gene-specific induction at the shorter time period is even more pronounced than in 
the A549 cells, in which a similar effect was observed under serum-starved conditions (Fig. 3a). In the absence 
of serum, all CpdA/DEX combination effects seemed to be blunted in the mICcl2 cells (Fig. 4a,b). However, in the 
presence of serum, DEX-mediated upregulation of FKBP5 expression was significantly downregulated by CpdA, 
whereas DUSP1 expression was significantly enhanced (Fig. 4c). These results correspond nicely with the effects 
in the A549 cells (Fig. 3c). In contrast, the expression of GILZ in the mICcl2 cells was not enhanced by combining 
CpdA with DEX, compared to DEX alone. At the longer time period (Fig. 4d), also in mICcl2 cells the effects again 
become less pronounced, in line with the results in Supplementary Figure S3c for FKBP5 in A549 cells.
In conclusion, the effect of CpdA on DEX-induced gene expression is both gene- and cell type-specific.
CpdA suppresses S211 phosphorylation of DEX-activated GR. Looking further into potential 
underlying mechanisms that may help explain the differential effects of the ligand combination compared to DEX 
alone, we speculated on a role for receptor phosphorylation and focused on phosphorylated Serine (Ser) 211 of 
GR, since this modification is considered a hallmark for GR transactivation23, 24.
As expected, activation of the receptor with DEX clearly enhanced the specific phosphorylation of Ser-211 
after 1 h of induction, compared to the background level (Fig. 5a). In contrast, CpdA alone did not induce phos-
phorylation of Ser-211, which correlates with the inability of CpdA alone to support GR-mediated transactivation 
of most GRE-driven genes (a.o. FKBP5 and GILZ). Yet, not all GRE genes behave similar as CpdA alone was 
found to induce DUSP1 in a context-dependent manner (Figs 3 and 4). Combining the two ligands resulted 
in a decreased phosphorylation compared to DEX treatment alone. Equal sample loading was verified using 
a non-phosphorylation-specific antibody and protein levels of actin served as an additional loading control. 
Quantification of the Western Blots was performed to ensure the accuracy of the conclusions (Fig. 5b). The sig-
nal of the total GR or the phosphorylated GR protein expression was normalised to the expression of the actin 
loading control. Correspondingly, we observed a significant decrease in Ser-211 GR phosphorylation when com-
bining CpdA and DEX, compared to DEX treatment alone. In contrast, no significant changes were apparent 
concerning the total GR protein levels.
These results indicate that combining CpdA with DEX diminishes GR phosphorylation at Serine 211, which 
may result in a context-dependent diminished transactivation potential of the receptor.
CpdA leaves nuclear translocation of DEX-bound GR unhampered. Using indirect immunofluo-
rescence to detect endogenous GRα in A549 cells, Fig. 5c illustrates that the unliganded receptor mainly resides 
in the cytoplasm. Following DEX treatment, the receptor clearly translocated to the nucleus. CpdA resulted in a 
mixed phenotype, with both nuclear and cytoplasmic GR proteins. Addition of CpdA before DEX did not affect 
the subcellular localisation compared to DEX induction alone. These findings indicate that a reduction in GR 
phosphorylation at Ser-211, by combining CpdA with DEX, does not impact the ability of the receptor to trans-
locate to the nucleus.
Combining CpdA with DEX results in a distinct GR cofactor profile. As cofactors regulate the tran-
scriptional activity of nuclear receptors (NR), we asked whether combining CpdA with DEX resulted in a differ-
ent cofactor recruitment pattern compared to either ligand alone. To this end, we applied the Microarray Assay 
for Realtime Coregulator-Nuclear receptor Interaction (MARCoNI) technology, in which interactions between 
a recombinant GRα-LBD-GST and peptides derived from known coactivator or corepressor proteins are mon-
itored25, 26. Coregulator-derived peptides are immobilized on a solid support, building a micro-array, and incu-
bated with the recombinant GR and a GST-specific antibody coupled with a fluorophore. Interaction strengths 
between the receptor and the NR binding motif in the peptides correlate with the amount of immobilized fluo-
rescent label26. As expected, DEX alone recruited several coregulators to GR, of which the 10 strongest binders 
are presented in Fig. 6a. These include mostly coactivators, such as nuclear receptor coactivator 1 (NCoA1) and 
PGC-1α. CpdA alone surprisingly showed no significant additional classic coregulator recruitment compared to 
the unliganded receptor profile. However, in line with a differential effect on gene expression (Figs 2–4), CpdA 
did subtly influence the cofactor profile of a DEX-bound receptor. We selected one peptide of the strong DEX-GR 
binders, i.e. NR0B2_106_128, which showed a significantly stronger interaction with the DEX/CpdA-activated 
GR than with the DEX-bound GR (Fig. 6b). This peptide is derived from the protein nuclear receptor subfamily 
0 group B member 2 (NR0B2), more frequently referred to as SHP.
predictions from the HGLMM fitted to the data, are shown on the original scale for FKBP5, DUSP1 and GILZ. 
The significance of gene-specific CpdA effects on DEX-induced gene expression, estimated as differences 
(on the transformed scale) to the gene-specific reference level CpdA/DEX, were assessed using a t-test. 
Furthermore, a t-test was used to test the difference (on the transformed scale) between Solvent and CpdA 
stimulation (*p < 0.05; **p < 0.01; ***p < 0.001).
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Figure 4. The effect of CpdA on DEX-induced gene expression is more pronounced in mICcl2 cells, in the 
presence of serum. (a) Serum-starved mICcl2 cells were pre-incubated with CpdA (10 µM) for 1 h, after which 
DEX (10 nM) was added for 2 h. Total RNA was extracted and subjected to RT-qPCR. Expression values were 
normalized to the reference genes Cyclo and HPRT using qBase+. Four independent replicates were performed. 
Means + SE, obtained as predictions from the HGLMM fitted to the data, are shown on the original scale for 
FKBP5, DUSP1 and GILZ. (b) Serum-starved mICcl2 cells were pre-incubated with CpdA (10 µM) for 1 h, 
after which DEX (10 nM) was added for 5 h. Total RNA was extracted and subjected to RT-qPCR. Expression 
values were normalized to the reference genes Cyclo and HPRT using qBase+. Three independent replicates 
were performed. Means + SE, obtained as predictions from the HGLMM fitted to the data, are shown on the 
original scale for FKBP5, DUSP1 and GILZ. (c) mICcl2 cells were pre-incubated with CpdA (10 µM) for 1 h, 
after which DEX (10 nM) was added for 2 h. Total RNA was extracted and subjected to RT-qPCR. Expression 
values were normalized to the reference genes Cyclo and HPRT using qBase+. Three independent replicates 
were performed. Means + SE, obtained as predictions from the HGLMM fitted to the data, are shown on the 
original scale for FKBP5, DUSP1 and GILZ (d) mICcl2 cells were pre-incubated with CpdA (10 µM) for 1 h, after 
which DEX (10 nM) was added for 5 h. Total RNA was extracted and subjected to RT-qPCR. Expression values 
were normalized to the reference genes Cyclo and HPRT using qBase+. Three independent replicates were 
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CpdA enhances the interaction of DEX-bound GRα with the cofactor SHP. To validate the above 
selected differential binder, we performed co-immunoprecipitation analysis in HEK293T cells with overexpressed 
Flag-SHP and HA-GRα in the presence or absence of CpdA and/or DEX. The interaction between SHP and 
GR was, as expected, ligand-dependent (Fig. 7a), and enhanced when combining CpdA with DEX. In addition 
to co-immunoprecipitation, we applied another protein-protein interaction technique, namely the Mammalian 
Protein-Protein Interaction Trap (MAPPIT)27, 28. MAPPIT is a two-hybrid system based on the restoration of 
a dysfunctional cytokine receptor signalling pathway through interaction between ‘bait’ and ‘prey’ chimeras, 
followed by a STAT3-dependent luciferase read-out. The GRα was used as a bait protein together with an empty 
control prey protein, the chaperone heat shock protein 90 (HSP90) and the protein of interest, SHP. We also 
included a family member of SHP, DAX-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical 
region on the X-chromosome, gene 1), to test whether the combined ligand effect is specific to SHP. As expected, 
upon activation of GR with DEX, the interaction between GR and its chaperone protein HSP90 was lost (Fig. 7b). 
This was not the case for CpdA, as described previously in Beck et al.29. However, combining CpdA with DEX 
disrupted the interaction with HSP90, similar to DEX activation alone. Concerning the interaction with SHP, 
we confirmed a stronger interaction to the receptor with the ligand combination than with DEX alone. This 
enhancement was specific to SHP, as the family member DAX-1 did not differ in binding to GR comparing DEX 
with CpdA/DEX. In conclusion, we show that CpdA enhances the DEX-mediated recruitment of the cofactor, 
SHP, to GR.
Discussion
Therapeutic use of classic glucocorticoids, such as Dexamethasone (DEX), is overshadowed by side effects and 
the occurrence of GC resistance. In the current work, we present data demonstrating an advantageous profile of 
GR ligand/modulator combinations, more precisely the combination of the full agonist DEX with the SEGRAM 
Compound A (CpdA).
Anti-inflammatory activities of CpdA treatment alone have already been established in diverse animal disease 
models9–15 and ex vivo, in human patient tissue16. GR-independent effects of CpdA have been reported15, 30–32, 
yet their underlying mechanisms are to date unresolved and may constitute cell-specific phenomena30. Given an 
observed GR-dependency of the suppression of inflammatory mediators by CpdA in particular cell models9, 12, 
anti-inflammatory effects of CpdA are at least partially GR-dependent.
Since the effects of CpdA and DEX are clearly not superimposable, we set out to study potential unique 
gene-modulatory properties of a combined effect. We discovered that combining this SEGRAM with DEX was 
capable to further enhance the NF-κB-targeting transrepression potential of the receptor in L929sA murine fibro-
blast cells. These results were further validated in A549 cells, showing strong suppression by the combined action 
of CpdA and a non-saturating DEX concentration (10 nM) on the TNFα-induced gene expression of TNFα, 
ICAM, CCL5 and CCL2. For the latter gene, we confirmed the combined effect was also visible at the protein 
level, supporting that this unique gene regulatory profile can be linked to functional chemokine protein levels.
Although CpdA does not stimulate GRE-driven reporter gene expression on its own, it can efficiently down-
regulate GRE-dependent promoter activity induced by DEX-activated GR, confirming previous results that were 
suggestive of a competitive effect between DEX and CpdA for binding to GR9. Remarkably, the order of ligand 
addition was important in the reporter assays, as simultaneous addition of CpdA and DEX had no effect com-
pared to DEX alone9, 33. However, using the more physiologically relevant read-out of mRNA expression levels, 
simultaneous addition resulted, at least for the GR targets tested here, in similar combined effects. Recently, CpdA 
combined with fluocinolone acetonide (FA), a glucocorticoid used mainly for topical application, was tested on 
GRE-dependent reporter constructs in murine immortalized keratinocytes34. In line with our results using DEX, 
CpdA strongly suppressed the FA-induced GRE-dependent promotor activity, supporting that the competitive 
effect is not GC ligand-specific. Additionally, a recent report by Malaise and colleagues35 studied the potential 
of ligand combinations using synovial fibroblasts, derived from patients with osteoarthritis (OA). In this study, 
ex vivo, long-term (7 days) treatment with CpdA led to lower prednisolone-induced leptin secretion and leptin 
receptor expression. The GC-mediated induction of leptin, which plays a detrimental role in OA, is believed to be 
caused by an enhanced GRE-dependent expression of GILZ, which was not induced by CpdA36. Corresponding 
to our findings at the endogenous gene level, in both aforementioned studies the order of ligand addition did not 
play a role since effects of CpdA together with FA or prednisolone were observed using simultaneous stimulation. 
The overall conclusions of these independent studies underscore the hypothesis that CpdA is capable of changing 
the activity of an agonist-bound GR.
Reporter gene experiments were confirmed at the mRNA level for FKBP5, the 51 kDa member of the immu-
nophilin protein family and a bona fide GRE-driven glucocorticoid target, in both lung and intestinal epithe-
lial cells. However, the influence of CpdA on the transactivation potential of DEX-activated GR appeared to be 
promoter- and cell type-dependent, as two GRE-dependent anti-inflammatory genes were unaffected or even 
enhanced. The induction of the GILZ gene upon CpdA/DEX was further only apparent in the A549 cells at 
certain culture conditions. DUSP1 expression - also known as MAP kinase phosphatase-1 (MKP1) - was signif-
icantly enhanced in both epithelial cells, when combining CpdA with DEX. This enhancement was even more 
pronounced in the mICcl2 cells, compared to the A549 cells. GRE-mediated DUSP1 expression in intestinal tissue 
performed. Means + SE, obtained as predictions from the HGLMM fitted to the data, are shown on the original 
scale for FKBP5, DUSP1 and GILZ. The significance of gene-specific CpdA effects on DEX-induced gene 
expression, estimated as differences (on the transformed scale) to the gene-specific reference level CpdA/DEX, 
were assessed using a t-test. Furthermore, a t-test was used to test the difference (on the transformed scale) 
between Solvent and CpdA stimulation (*p < 0.05; **p < 0.01; ***p < 0.001).
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was proven crucial to protect against TNFα-induced inflammation37. Consequently, our results underscore the 
potential advantage of selectivity for specific GRE elements following ligand combinations. Fitting previous con-
clusions that CpdA does not stimulate GRE-driven gene expression11, 12, 38, we observed no effect by CpdA alone 
on the reporter gene assays and particular endogenous genes. Surprisingly however, at the shorter time period 
and depending on the cellular context, we did observe a mild induction of DUSP1 expression by CpdA alone. This 
gene-specific induction was even more pronounced in the intestinal epithelial cells, where we observed a strong 
enhancement of DUSP1 expression by CpdA alone, comparable to levels obtained with a non-saturating concen-
tration of DEX alone. This is in contrast to the lack of DUSP1 induction by CpdA in another intestinal epithelial 
cell line Caco-2 cells, in which GR was however transiently transfected39. This differential effect of CpdA may 
be due to differences in GR levels, which could result in changes in ligand sensitivity, as proposed by Robertson 
et al.40. Recently, another study31, using airway smooth muscle cells, reported a CpdA-induced expression of 
DUSP1, but not GILZ, both at the mRNA and protein level. Similar to our results, this occurred after a short time 
period, but in a steroid-resistant context, and was found to be GR-independent31. As a final explanation, CpdA 
may degrade more quickly in the cells as compared to the stable steroidal DEX, which is why a consideration of 
future treatment strategies based on the advantages of a dual GR ligand/modulator combination would definitely 
require stabler SEGRAM molecules15.
Ligand competition for GR molecules in the cell has been suggested as an underlying mechanism for the com-
bined effect, whereby CpdA could act as a partial GR antagonist9, 34, 35. In the current work, we present evidence 
for potential other mechanisms that may help explain the differential effect of the ligand combination compared 
to DEX alone.
CpdA does not elicit the same phosphorylation status of the GR as DEX does, and it induces a different 
conformation of GR following limited trypsin protease digestions9. We hence hypothesized that CpdA may also 
modulate a DEX-triggered GR, subtly changing GR conformation and thus leading to functional differences. This 
hypothesis would fit with the finding of modest differences in cofactor recruitment patterns using the MARCoNI 
assay comparing a CpdA/DEX-activated GR to DEX activation alone. As this assay was done using recombinant 
Figure 5. CpdA suppresses S211 phosphorylation of DEX-activated GR, but has no effect on its nuclear 
translocation. (a) A549 cells were pre-incubated with CpdA (10 µM) for 1 h, after which DEX (1 µM) was added 
for 1 h. Total cell lysates were prepared and subjected to Western Blot analysis. Actin served as a loading control 
(n = 3, representative figure). (b) Quantification of (a). Expression values, obtained with Image J analysis of 
three independent replicates, were normalized to the loading control Actin. Means + SE, obtained as predictions 
from the HGLMM fitted to the data, are shown on the original scale for pGRα S211 and GRα. (c) A549 cells 
were pre-incubated with CpdA (10 µM) for 1 h, after which DEX (1 µM) was added for 1 h. After fixation, cells 
were subjected to immunostaining with anti-GR, followed by anti-rabbit-Alexa 488 as a secondary Ab. DAPI 
staining was used to visualize nuclei (n = 2, representative figure). The significance of CpdA effects on DEX-
induced protein expression, estimated as differences (on the transformed scale) to the reference level CpdA/
DEX, were assessed using a t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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Figure 6. Combining CpdA with DEX results in a distinct GR cofactor recruitment profile. (a) MARCoNI 
assay result with recombinant GRα-LBD-GST stimulated with DEX (1 µM) and/or CpdA (10 µM). Interaction 
between the recombinant GR and the immobilized cofactor-derived peptides are detected with an anti-GST 
antibody labeled with Alexa 488, after several washing steps to eliminate unbound GR proteins. The top 10 
interacting peptides with DEX-bound GR-LBD are shown here. Data was normalized via LOESS regression 
(Mean + SEM, n = 3). (b) Detail result of (a): SHP (=NR0B2) peptide interacts stronger with CpdA/DEX-
stimulated GR compared to DEX-bound GR. Statistical analysis via one-way ANOVA (p-value < 0.001) with 
post-hoc t-test (corrected for multiple testing) (***p < 0.001).
Figure 7. CpdA enhances the interaction of DEX-bound GRα with the cofactor SHP (a) Co-
immunoprecipitation between Flag-SHP and HA-GRα overexpressed in HEK293T cells (ratio GR/SHP was 
1/5). Cells were stimulated with CpdA (10 µM) 1 h before DEX (1 µM) and lysed 3 h after DEX stimulation 
(n = 4, representative figure). (b) Mammalian protein-protein interaction technique (MAPPIT). Empty prey 
is used as negative control, HSP90 prey as selective control. Cells were stimulated with leptin (100 ng/ml) 
and leptin in combination with DEX (1 µM) and/or CpdA (10 µM) for 24 h or were left untreated. Luciferase 
measurements were performed in triplicate (normalized by β-galactosidase expression) and normalized 
by untreated values. Reporter activities are expressed as relative induction factor versus Solvent. Three 
independent replicates were performed. Means + SE, obtained as predictions from the HGLMM fitted to 
the data, are shown on the original scale. The significance of ligand effects on binding activity, estimated as 
differences (on the transformed scale) to the reference level DEX, were assessed using a t-test (*p < 0.05; 
**p < 0.01; ***p < 0.001).
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GRα-LBD, any change in cofactor binding is conformation-dependent, as no other cellular factors are present. 
Furthermore, we found a decrease in Serine-211 phosphorylation after combined treatment, which could result 
from a different GR conformation. Several studies have appointed this specific phosphorylation as a hallmark 
for the transactivation potential of the receptor9, 23, 41, and consequently, this reduction may explain the observed 
changes in GRE-driven gene expression. Taken together, our findings suggest an allosteric regulation by CpdA of 
the DEX-bound receptor.
Combining CpdA with DEX still releases the chaperone protein HSP90, resulting in GR translocation to the 
nucleus. Phosphorylation of Ser-211 may not be a prerequisite for nuclear translocation, as CpdA does not induce 
this PTM but still induces (partial) nuclear accumulation of GR9, 13, 14, 33, 39, 42. In keeping with this, CpdA/DEX 
decreased Ser-211 phosphorylation, yet GR nuclear accumulation was unaffected.
Following MARCoNI, we found no significant additional cofactor recruitment by CpdA alone, compared 
to unliganded GR. In support, Ronacher and colleagues found no recruitment by CpdA-GR of the full-length 
steroid-receptor coactivator (SRC-1) and GR-interacting protein 1 (GRIP1)43. However, other dissociative ligands 
did support GR coactivator recruitment, albeit with profiles slightly different from the classic agonist DEX. For 
instance, AL438 showed a similar recruitment of GRIP1 compared to DEX-activated GR, but the interaction with 
the coactivator PGC-1α was reduced44.
Studying the GR cofactor recruitment profile in more detail, we found that the most prominent interaction 
influenced by CpdA/DEX was between GR and SHP, compared to DEX alone. Borgius and colleagues45 showed 
that SHP inhibits DEX-induced transcriptional activity of the GR in the liver, by antagonizing PGC-1α coac-
tivation of the receptor. One NR-binding LXXLL-related motif, crucial for the inhibitory effect, showed high 
homology with the NR-binding motif of PGC-1α. As such, this corepressor was able to directly compete with 
PGC-1α for binding onto the AF-2 domain of GR. Surprisingly, we identified the same LXXLL-related motif 
within the peptide that interacted significantly more strongly with the DEX/CpdA-activated GR compared to the 
DEX-bound GR in MARCoNI. This finding suggests that the specific GR profile induced by the ligand combina-
tion could be the result of enhanced SHP recruitment following a competition between coactivators. A similar 
competitive mechanism was proposed for the family member of SHP, DAX-1, that directly modulates GR signal-
ling though binding competition with the coactivator GRIP1. As such, DAX-1 specifically inhibits DEX-induced 
transactivation, while the GR transrepression potential remains unhampered46. Here, the enhanced interaction 
with CpdA/DEX-stimulated GR was, however, found to be specific for SHP. This finding points to a differential 
affinity of the two family members for a specific GR conformation, triggered here by CpdA/DEX. Follow-up stud-
ies are warranted to further investigate the possible role and underlying mechanisms of SHP, and more generally 
NR0B family members, on GR-mediated gene regulation and in favouring of GR-mediated transrepression over 
transactivation.
In conclusion, although CpdA does not stimulate a recombinant GRE-driven reporter on its own, we have 
shown it can influence the gene regulatory activity of DEX-activated GR. Ligand combinations may induce an 
advantageous GR-profile in epithelial cells, modulating GR to cooperatively suppress inflammation in combina-
tion with enhanced expression of particular anti-inflammatory genes. At the molecular mechanistic level, this 
unique gene regulatory profile is explained by a decrease in Serine-211 GR phosphorylation coinciding with a 
stronger recruitment of, among others, the corepressor SHP.
Ligand combinations may be a way forward to obtaining stronger therapeutic effects with lowered concentra-
tions of single compounds, thus possibly circumventing particular side effects.
Methods
Cell Culture. Murine L929sA fibrosarcoma cells, human A549 lung epithelial cells and human HEK293T 
cells were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and grown at 37 °C under 5% CO2. Murine intestinal crypt cells (mICcl2) were a kind gift of the lab 
of Thomas Brunner47–49. These intestinal epithelial cells were maintained in DMEM/Ham’s F-12 (1:1, contain-
ing NaHCO3 (2.438 g/L) and L-alanyl-L-glutamine (2 mmol/L, as Glutamax), Gibco) supplemented with 10% 
charcoal stripped FBS (DCC-FBS), 60 nmol/L sodium selenate, 5 µg/ml apo-transferrin, 10 ng/ml murine EGF, 
1 nmol/L triiodothyronine, 5 µg/ml insulin, 20 mmol/L HEPES and Gentamicin. mICcl2 cells were grown at 37 °C 
under 8% CO2.
Cytokines and Reagents. Recombinant murine TNFα was produced and purified to 99% homogeneity 
at the VIB protein service facility. A stock solution (1.26 × 108 IU/ml) was prepared in medium, aliquoted and 
stored at −80 °C. TNFα was used at a final concentration of 2000 IU/ml. Dexamethasone (DEX) was purchased 
from Sigma-Aldrich. A stock solution was prepared in ethanol (10−2 M) and stored in −20 °C. Compound A 
(CpdA) was synthesized as described by Louw et al.50. CpdA powder was aliquoted and stored in −80 °C. Before 
use, the powder was dissolved in ethanol to a stock solution (10−2 M). Luciferase (luc) reagent was prepared as 
previously described51.
Reporter assays. L929sA (by standard CaPO4 procedure) and A549 cells (by lentiviral transduction) were 
stably transfected with p(GRE)2-50-Luc+ or p(IL6-κB)3-50hu.IL6P-luc+ reporter gene constructs, generated as 
described previously51. Cells were induced as indicated in the figure legends, after which luciferase assays were 
performed according to the protocol of Promega Corp. For each biological replicate, luciferase measurements 
were performed at least in triplicate and normalized, where possible, by measurement of β-galactosidase (β-gal) 
levels with the Galacto-Light kit (Tropix). Light emission was measured with a TopCount NXT luminometer 
(Perkin-Elmer).
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Cell viability assay. Cell viability assay was performed to quantitate ATP generated by metabolically active 
cells using a CellTiter-Glo luminescent cell viability assay kit (Promega) according to the manufacturer’s instruc-
tion. Briefly, 1.105 cells were cultured in 96-well plates. After 24 h cells were induced with respective compounds 
as indicated. Subsequently, 25 μl of CellTiter-Glo reagent was added to lyse the cells. After 10 min incubation at 
room temperature, the luminescence was recorded with the TopCount NXT luminometer (Perkin-Elmer).
qRT-PCR. A549 or mICcl2 cells were induced as indicated and total solvent concentration was kept simi-
lar in all conditions. The cells were serum-starved or steroid-starved with charcoal stripped FBS (DCC-FBS) 
beforehand as indicated. For the transrepression experiments, A549 cells were serum-starved (see Fig. 2 and 
Supplementary Figure S2). RNA was isolated using RNeasy Micro Kit (Qiagen) and mRNA was reverse tran-
scribed to cDNA with the PrimeScript RT kit (TaKaRa). cDNA was analysed by real-time PCR with a SYBR 
Green master mix (Roche). Primer sequences are available on request.
ELISA. Detection of CCL2 secretion in A549 supernatant was performed according to manufacturer’s proto-
col using Ready-SET-Go! ELISA Kit (eBioscience).
SDS-PAGE, Western blot analysis and co-immunoprecipitation. After deprivation of serum, A549 
cells were pretreated for 1 h with CpdA (10 µM) and stimulated with DEX (10 nM or 1 µM) for 1 h, 2 h or 5 h. After 
washing with ice-cold PBS, cell lysates were prepared using SDS sample buffer (62.5 mM Tris-HCl pH 6.8, 2% 
SDS, 10% glycerol, 0.01% bromophenol blue) followed by standard Western blotting and antibody probing pro-
cedures. Equal loading was assayed via a loading control. Anti-GR (H-300) and anti-phospho-Ser-211 GR were 
purchased from Santa Cruz Biotechnology and Cell Signaling Technology, respectively.
For co-immunoprecipitation, HEK293T cells were transiently transfected using the calcium phosphate 
precipitation technique with FLAG-SHP and HA-GRα at a ratio of 5 to 1. Twenty-four hours later, cells were 
serum-starved overnight, 1 h pretreated with CpdA (10 µM) followed by DEX (1 µM) stimulation. Three hours 
later, cells were lysed (50 mM Tris-HCl pH 7.5, 125 mM NaCl, 5% glycerol, 0.2% NP40, 1.5 mM MgCl2 and 
Complete Protease Inhibitor Cocktail (Roche)) and incubated overnight with anti-FLAG beads (anti-FLAG M2 
affinity gel, Sigma Aldrich) on a rotor at 4 °C. These beads were blocked before for 1 h at 4 °C, using undiluted 
StartingBlockTM (TBS) Blocking buffer (Thermo Scientific). Following overnight incubation and three washing 
steps, the samples were eluted using Laemmli buffer, boiled for 5 min at 95 °C and stored at −20 °C. Finally, 
standard western blotting and antibody probing procedures using anti-HA rat (Roche), anti-FLAG rabbit (Sigma 
Aldrich) and anti-actin (as loading control) mouse antibody (Sigma Aldrich) were performed.
Immunofluorescence. A549 cells, seeded on coverslips and serum-deprived overnight, were induced as 
indicated. After fixation, endogenous GRα was visualized using rabbit anti-GR (H-300) antibody (Santa Cruz 
Biotechnology) followed by donkey Alexa Fluor 488 anti-rabbit IgG (Molecular Probes, Invitrogen). Cell nuclei 
were stained with DAPI DNA staining (300 nM, Invitrogen).
MAPPIT. Constructs were generated by standard PCR- or restriction based cloning procedures. The gener-
ation of the pCLG-GRα plasmid (GR-bait chimera) and empty prey control was described previously by Beck 
et al.29. The prey plasmids pMG2-HSP90AA1 (HSP90-prey chimera), pMG1-DAX-1 and pMG1-SHP were cre-
ated by Gateway transfer of the full size DAX-1 and SHP ORFs, obtained as entry clones from the hORFeome 
collection (hORFeome 8.1), into the Gateway compatible pMG1 or pMG2 prey destination vector as described 
earlier52. The pXP2d2-rPAP1-luciferase reporter has been described elsewhere53. For the MAPPIT analysis, 10 000 
HEK293T cells/well were seeded in 96-well plates. One day later, cells were transiently co-transfected using the 
calcium phosphate precipitation technique with the GRα-bait plasmid, the STAT3-responsive rPAP1-luc reporter 
plasmid and the desired prey-plasmid. 24 h after transfection, cells were stimulated with leptin (100 ng/ml) 
or leptin in combination with DEX (1 µM) and/or CpdA (10 µM) for another 24 h or were left untreated. 
Luciferase measurements of total cell lysates were performed as described above, and performed in triplicate 
(normalized by β-galactosidase expression).
MARCoNI. The MARCoNI assays were performed in a PamStation96 controlled by the EvolveHT software 
(PamGene International BV). Nuclear Receptor PamChip Arrays (PamGene International BV) with the immobi-
lized coregulatory-derived peptides were incubated with the recombinant protein GRα-LBD-GST (Invitrogen). 
The reaction mixture for each array consists of 1 nM GRα-LBD-GST and 25 nM Alexa Fluor 488-conjugated 
anti-GST antibody (Invitrogen) in nuclear receptor buffer F (Invitrogen) in the absence or presence of GR lig-
ands at the indicated concentrations. The MARCoNI procedure has been described in detail previously25, 26. 
Receptor-peptide interaction strengths are reflected by fluorescent signal intensities. Image analysis consists of 
automated spot finding followed by quantifications using the BioNavigator software (PamGene International BV). 
The signal-minus-background value was subsequently used as the quantitative parameter for binding. Data was 
fitted according to a Loess regression using a customized R script.
Statistical Analysis. A Hierarchical Generalized Linear Mixed Model (HGLMM) (fixed model: poisson dis-
tribution, log link; random model: gamma distribution, log link) as implemented in Genstat v18 has been fitted 
to reporter assay, qPCR, ELISA and MAPPIT data. In case of qPCR, the HGLMM model has been fitted to the 
data of multiple genes jointly. The linear predictor vector of the fluorescence or luminescence (for ELISA) values 
can be written as follows:
µ η β= = + vX Zlog( ) ,
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where the matrix X is the design matrix for the fixed terms (e.g. for qPCR: GENE, INDUCTION) and their inter-
action, β is their vector of regression coefficients, Z is the design matrix for the random term (e.g. REPLICATE), 
and ν is the corresponding vector of random effects having a gamma distribution. T statistics were used to assess 
the significance of effects (on the transformed scale) by pairwise comparisons to the reference level (as indicated 
in the figure legends). Estimated mean values and standard errors (SE’s) were obtained as predictions from the 
HGLMM, formed on the scale of the response variable.
The MARCoNI data was normalized using Loess regression, followed by ANOVA and Tukey’s multiple com-
parison post-hoc t-test.
Statistical analyses were carried out using GenStat (Release 18) and GraphPad Prism (version 7) Software.
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